Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

Excellent Tuco.

Thanks very much to all who responded to my query about success rates - very helpful.

marwalker: yes that is what AK said that big pharma said. But interestingly OXB did not test for CD8 in the early studies. Said, if I remember rightly, that was because of lack of material (but couldn't that have been included in the protocol if considered important, that's always puzzled me, perhaps OXB did not think it that important at that time - maybe they already thought that humoral immunity was key or at least the major arm of the response). I don't think we know whether people who make lots of antibody also generate lots of CD8+ cells, or whether people tend to do one or the other in response to Trovax. Interesting, but perhaps not a lot more can be deduced at the moment - at least OXB will no doubt be giving it their best attention which will do for me!

rrr